Santarus, Inc.

Published Date: 14/06/2011
Category: Therapies & Markets

Research Report Decription

Santarus, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Santarus, Inc. required for business and competitor intelligence needs
• Study of the major internal and external factors affecting Santarus, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Santarus, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Santarus, Inc.
• Intelligence on Santarus, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Santarus, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Santarus, Inc. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Santarus, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Santarus, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Santarus, Inc.

Paper Highlights:

Santarus is a specialty pharmaceutical company engaged in acquiring, developing and commercializing products that address the needs of patients treated by gastroenterologists and other physicians. The company markets two products, including Zegerid (omeprazole/sodium bicarbonate) for the treatment of certain upper gastrointestinal diseases and disorders, and Glumetza (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It primarily operates in the US. The company is headquartered in San Diego, California and employed 335 people as of January 31, 2010. The company recorded revenues of $172.5 million during the financial year (FY) ended December 2009, an increase of 32.5% over FY2008. The operating profit of the company was $34.1 million during FY2009, as compared to an operating loss of $19.2 million in FY2008. The net profit was $32.1 million in FY2009, as compared to a net loss of $18.5 million in FY2008.